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Abstract
Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVD) are commonly interconnected, and this coin-
cidence negatively influences patients’ mortality and morbidity. On the basis of the current available data originating mainly from 
cardiovascular studies epicardial fat (EF) has been proposed as a marker of cardiovascular risk.
This review is focused on a potential role of epicardial fat as a new biomarker for risk stratification of COPD patients.
Epicardial fat may present an important link between chronic obstructive pulmonary disease and cardiovascular diseases, mainly 
coronary artery disease.
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Introduction 
Chronic obstructive pulmonary disease 
(COPD) and cardiovascular diseases (CVD) are 
commonly interconnected , and this coincidence 
negatively influences patients’ mortality and 
morbidity. In clinical practice it is usually hard 
to stratify COPD patients according to their car-
diovascular risk, and nowadays we are looking 
for new biomarkers. Epicardial fat (EF) has been 
proposed as a marker of cardiovascular risk, and 
these days there are available data mainly from 
cardiovascular studies. Recently, as well as the 
relationship between COPD and EF has been stud-
ied. This review shows measurement methods 




Epicardial fat is the visceral thoracic fat 
deposition located between the myocardium 
and the visceral pericardium (Fig. 1) [1]. Epi-
cardial fat is highly metabolically active — it 
produces many cytokines, which, for example, 
play a role in atherosclerosis progression [2]. Due 
to its activity, it should be distinguished from 
paracardial fat (adipose tissue located external 
to the parietal pericardium) and pericardial fat 
(paracardial fat with all the adipose tissue lo-
cated internal to the parietal pericardium) [3]. 
In fact, the term pericardial fat is often used to 
describe all the adipose tissue located in the 
pericardial sac [4].
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EF is usually found in atrioventricular and 
interventricular grooves extending to the apex of 
the heart, specifically between the myocardium 
and visceral pericardium [5, 6]. 
Epicardial fat measurement
For the measurement of epicardial fat, a few 
modalities could be used. The ‘gold standard’ is 
generally considered cardiac magnetic resonance 
(Fig. 2) [3]. This method offers excellent spatial 
resolution and is the only imaging modality in 
which volumetric quantification of epicardial fat 
has been validated ex vivo [7, 8]. The advantages 
are obvious — no radiation or iodinated contrast 
exposure. On the other hand, this method pres-
ents with many disadvantages amongst which 
are its high costs, time requirements and lower 
availability in some centres.
The chest computed tomography (CT) scan 
is an alternative that can be used for the mea-
surement of epicardial fat (Fig. 3). This method 
was used widely in previous studies, especially 
because a chest CT was performed due to other 
indications like pulmonary embolism, calcium 
score measurement, emphysema quantification, 
etc. It offers high spatial resolution and attenu-
ation value ranges can be defined to allow for 
either manual or semi-automatic quantification 
of adipose tissue [9, 10]. Advantages are a good 
resolution, excellent reproducibility and the pos-
sibility of volumetric quantification. The disad-
vantage is the exposure to both ionizing radiation 
and iodine-containing contrast.
Figure 1. The figure shows a cross-section of the heart wall. Numero-
us adipocytes (red arrows) are present in the subepicardial connective 
tissue. The epicardium is marked with a black arrow, the myocardium 
(blue arrow) is captured at the bottom of the slide. Magnification 200 ×
 Figure 2. Cardiac magnetic resonance imaging assessment of peri-
ventricular epicardial fat. TrueFISP magnetic resonance image in short 
axis. End-diastole. Arrows depict epicardial fat
 Figure 3. Computed tomography assessment of periventricular epicar-
dial fat. Computed tomography after i.v. application of contrast agent in 
the parasagittal plain. End-diastole. Arrows depict epicardial fat
The third option is echocardiography, which is 
the most accessible and affordable imaging modality 
(Fig. 4). It is important to notice that 2D echocardi-
ography does not offer measurement of the amount 
of epicardial fat like volumetric measurement 
during cardiac magnetic resonance or computed 
tomography imaging. This is possible only using 3D 
echocardiography, though this method is not widely 
available and it is time-consuming. Instead of the 
measurement of epicardial fat volume, epicardial fat 
thickness is used. EF is identified as a hypoechoic 
space anteriorly to the right ventricle wall, and 
its thickness is measured between the epicardial 
surface and pericardium identified by the sliding 
between these two layers [11]. This is measured 
over the free wall of the right ventricle in diastole 
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and omentin [21]. Adiponectin has antidiabetic, 
antiatherogenic, antioxidative and anti-inflam-
matory properties [22]. This adipokine also in-
hibits the production of tumour necrosis factor 
alpha (TNF-a) and other inflammatory pathways 
in adipocytes and macrophages, producing an 
anti-inflammatory effect [23]. Also, EF produc-
es a high amount of adrenomedullin, which is 
a potent vasodilator peptide [24]. It has also been 
proposed that adrenomedullin has antioxidant 
properties antagonising oxidative stress induced 
by angiotensin II [25].
EF is also a producer of pro-inflammatory 
adipokines like interleukin 1 (IL-1), interleukin 8 
(IL-8), interleukin 6 (IL-6) and TNF-a [26, 27]. IL-6 
is considered to be one of the key adipokines in-
volved in atherosclerotic plaque development [28] 
as well as in insulin resistance [29]. TNF- a is an-
other important adipokine produced by epicardial 
fat adipocytes. Its serum level is elevated in obese 
individuals where it actually worsens insulin 
resistance. TNF-a is also a potent vasoconstrictor 
[30]. It decreases adiponectin production and 
stimulates the production of other pro-inflam-
matory adipokines [31].
Epicardial fat and cardiovascular diseases
There are many studies available on epicar-
dial fat in patients with CVD. Higher amounts of 
EF were found to be related to the presence of 
coronary syndromes and weakening of atheroma-
tous plaques [32, 33]. There is also data showing 
that individuals with a higher amount of EF have 
a more severe coronary plaques, indicating that 
the thickness of epicardial fat plays a key role in 
the progression of coronary atherosclerotic dis-
ease [34]. EF thickening is thus considered a risk 
factor of coronary plaque formation and their 
vulnerability [35]. An independent association 
between pericardial fat and cardiovascular risk 
factors, coronary calcification and the presence of 
carotid artery disease has also been demonstrat-
ed [11]. Further researches on atrial fibrillation 
(AF) and epicardial fat provide interesting data. 
Numerous studies support the association of epi-
cardial fat with the presence of AF [36]. Data from 
the Framingham Heart Study suggests that EF vol-
ume is independently associated with prevalent 
AF [37]. Many pathophysiological mechanisms 
are discussed as possible causes. EF is a known 
source of reactive oxygen species [38], which may, 
according to some authors, play a role in the gen-
esis of AF [4]. Autonomic dysfunction may also 
contribute, as the autonomic nervous system is 
thought, to play a crucial role in the initiation and 
Figure 4. Echocardiography assessment of periventricular epicardial 
fat. End-diastole. Arrows depict epicardial fat
in three subsequent cardiac cycles [12]. According 
to some recommendations, measurement during 
systole is also used [13], but most authors use 
diastolic measurement to correlate with MRI 
and CT imaging outcomes. The most discussed 
aspect is the need to identify the pericardium as 
this can sometimes be very difficult, especially 
in an obese individual where good quality images 
are not usually available. On the other hand, in 
large population studies where there is a need 
for economic, safe and fast examinations, this 
approach to epicardial fat measurement seems 
justifiable, especially if we consider that a good 
correlation with MRI results has been shown 
(r = 0.91, p = 0.001) [14]. 
Epicardial fat physiology
Epicardial fat originates from the splanchno-
pleuric mesoderm [15], in contrast to paracardial 
fat, which is derived from the primitive thoracic 
mesenchyme [16]. Epicardial fat is directly per-
fused by the coronary arteries and thus it has 
a direct paracrine effect on the myocardium [17]. 
Its functions include lipid storage for myocardial 
energy, thermoregulation and the protection of au-
tonomic ganglia and nervous tissue [4]. There have 
also been discussions regarding further potential 
functions such as its effect on local distribution 
and regulation of vascular flow [16]; its role as an 
immune barrier in the protection of the myocar-
dium and coronary arteries from inflammatory 
and pathogenic substances [18] as well as the 
mechanical protection of the coronary arteries. 
EF is a highly metabolically active organ and 
a major source of anti-inflammatory and proin-
flammatory adipokines [19, 20]. 
Of the anti-inflammatory adipokines, the 
most important are adiponectin, adrenomedullin 
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maintenance of AF [39]. Ganglionated plexi are 
located in the epicardial fat and their dysfunction 
could lead to AF development as well [40].
Epicardial fat and chronic obstructive 
pulmonary disease
In the field of COPD and EF, only a  few 
studies have been performed. Zagaceta et al. [1] 
enrolled 171 stable COPD patients (mostly stage I  
and II according to GOLD 2009 guidelines) and 
70 controls (ex-smokers) in whom the amount of 
EF was measured using CT imaging. Multivariate 
analysis exploring the association of EF volume 
and COPD diagnosis, after adjusting for the Charl-
son Comorbidity Index, showed that the presence 
of COPD was a statistical predictor of EF volume 
(b coefficient 28.86; 95% CI: 7.6–51.1; p = 0.008). 
Moreover, EF was independently associated 
with modifiable CVD risk factors like smoking 
history, BMI and decreased exercise capacity. As 
was shown in a previous study [41], a higher EF 
volume predicts higher CVD risk in communi-
ty-based adults without a history of CVD. This 
could represent a strong link between COPD and 
CVD risk. There is also increasing evidence that 
adipose tissue is a significant contributor to the 
systemic inflammation load in COPD [42, 43]. 
Visceral fat plays a main role where adipose 
tissue dysfunction, including enhanced adipose 
tissue inflammation, was described and could 
contribute to the low-grade inflammation, which 
has been described in patients with COPD. For 
example, excessive visceral fat mass was positive-
ly associated with all-cause and cardiovascular 
disease mortalities as well as with a higher serum 
level of IL-6 [43]. It is unclear whether pulmonary 
impairment or poor lifestyle predispose to exces-
sive visceral fat accumulation.
In another study, Kiraz et al. [44] enrolled a sam-
ple of 157 COPD patients and 45 controls where the 
epicardial fat thickness was measured using echo-
cardiography. EF thickness was higher in the COPD 
patients in comparison with the controls (p < 0.05). 
In the same study, an inverse correlation between 
the BODE index and EF thickness was found. Sim-
ilarly, the study by Demir et al. [45] found higher 
EF thickness in those with COPD in comparison to 
healthy subjects (p < 0.001). However, the study by 
Kaplan et al. [12] paradoxically found EF thickness 
to be lower in patients with COPD and systolic 
dysfunction of the right ventricle.
The important aspect and possible future 
direction of research is the relationship between 
EF volume and different COPD phenotypes, as 
COPD is a highly heterogeneous disease, and the 
same cardiovascular risk cannot be presumed for 
all phenotypes.
Furthermore, data regarding the possible ef-
fect of bronchodilator treatment in the reduction 
of cardiovascular disease risk is missing.
Conclusion
Epicardial fat may present an important link 
between chronic obstructive pulmonary disease 
and cardiovascular diseases, mainly coronary ar-
tery disease. Currently, the data available tends to 
support the hypothesis of a higher volume of EF in 
COPD patients with a possibly subsequent higher 
level of systemic inflammation. Measurement of 
EF thickness could present a novel approach to 
CVD risk stratification in patients with COPD. 
However, more robust data is needed.
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